The information within this section of the website is intended for UK Healthcare Professionals. Members of the public, Prostap DCS prescribed patients and UK Practice Managers should follow the relevant links.

Feel comfortable with our support materials

comfortablewithadministration-figure1

Administration video and guide

The 3-minute video explains the 4 steps required to administer Prostap DCS.

The A4 Administration Guide can be kept close by as a quick, easy-to-follow reminder of how to administer Prostap DCS.

viewhcpmaterials-button1

viewhcpmaterials-figure-2

Prostate cancer diagnosis and treatment flipchart

The flipchart will help you to have more in-depth discussions with your patient about their prostate cancer, its diagnosis and treatment. It has been designed so that your patient can be shown simplified diagrams or text on one side, while additional information is available to you on the other side.

 

Prostate cancer guide to anatomy and tumour stages tear-off pad

This guides you through a discussion with your patient about the anatomy of their prostate and tumour stages. Once the conversation has finished, you can tear a copy of the sheet off for the patient and keep the other.

 

LHRH agonist flashcard

A visual aid to help you discuss what an LHRH agonist is, why it is being prescribed and what the differences are with your patient. It comes with a useful section using straightforward language to explain the difference between the most commonly used LHRH agonists.

Practice Manager website

The Prostap DCS website includes a section for Practice Managers. It explains how prescribing Prostap DCS can bring a cost benefit to a GP practice, helping it to make tangible savings and optimise income. You or your Practice Manager can even request a personalised budget impact model.

comfortablewithadministration-figure1

PA item animation

Personally administered (PA) items can be a valuable source of monthly income to a GP practice. But this income can also be frequently overlooked, perhaps because the process may appear a little confusing or time-consuming.
In reality, claiming PA items couldn’t be simpler. So, simple, in fact, we’ve summarised the whole process into a two-minute animation for you to watch.

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. IMS Midas standard unit sales. (1,000) MAT/JAN/2014.
  2. Takeda UK Ltd. Data on file, DF120604(2).
  3. The Leuprolide Study Group. N Eng J Med 1984;311:1281–1286
  4. Sharifi R, Ratanawong C et al. Advanced Drug Delivery Reviews 1977;28:121–138.
  5. D’Amico A V, Chen M et al. JAMA 2008;299:289–295
  6. Kienle E, Lubben G. Urol Int 1996;56(Suppl 1):23–30.
  7. Tunn U W, Wiedey K. Prostate Cancer Prostatic Dis 2009;12:83–87
  8. Prostap SR DCS. Summary of Product Characteristics.
  9. Prostap 3 DCS. Summary of Product Characteristics.
  10. Takeda UK Ltd. Data on file, UK/DF/1405/0020. Available At http://www.pharmatimes.com/news/takeda_launches_new_prese ntation_of_prostap_980760 Last accessed June 2017
  11. Health and Safety Sharp Instruments in Healthcare Regulations 2013. Available at: http://www.hse.gov.uk/pubns/hsis7.pdf. Last accessed June 2017
  12. National Institute for Health and Care Excellence (NICE). Clinical guideline CG175. Full guideline, 2014.
  13. Abdouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513–526
  14. Barnes R et al. Study M86-049 Report.
  15. MHRA Prostap® SR DCS UKPAR, 2014. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con120
    442.pdf
    . Last accessed June 2017
  16. Jocham D. Urol Int 1998;60:18–24.
  17. Mottet N et al. European Association of Urology Guidelines on Prostate Cancer, Update March 2016.
  18. D’Amico et al. JAMA 2004;292(7):821–827.
  19. Mottet N et al. Eur Urol 2012;62:213–219.
  20. Wechsel HW et al. Eur Urol 1996;30(Suppl 1):7–14.
  21. Takeda UK Ltd. Data on file. DF121104.
  22. Takeda UK Ltd. Data on file. DF121106.

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers.

If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a
Practice Manager

Yes

I am a
Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.